<SEC-DOCUMENT>0001513162-20-000136.txt : 20200702
<SEC-HEADER>0001513162-20-000136.hdr.sgml : 20200702
<ACCEPTANCE-DATETIME>20200702170513
ACCESSION NUMBER:		0001513162-20-000136
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200702
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200702
DATE AS OF CHANGE:		20200702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anixa Biosciences Inc
		CENTRAL INDEX KEY:			0000715446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				112622630
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37492
		FILM NUMBER:		201010610

	BUSINESS ADDRESS:	
		STREET 1:		3150 ALMADEN EXPRESSWAY, SUITE 250
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95118
		BUSINESS PHONE:		408-708-9808

	MAIL ADDRESS:	
		STREET 1:		3150 ALMADEN EXPRESSWAY, SUITE 250
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ITUS Corp
		DATE OF NAME CHANGE:	20140902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COPYTELE INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body vlink=#954f72 link=blue lang=EN-US> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>UNITED STATES</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>WASHINGTON, D.C. 20549</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>FORM 8-K</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>CURRENT REPORT</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>PURSUANT TO SECTION 13 OR SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Date of Report (Date of earliest event reported):&nbsp; July 2, 2020</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>ANIXA BIOSCIENCES, INC.</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>(Exact name of registrant as specified in its charter)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <div style=page:WordSection1 align=center> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=194 style="WIDTH:145.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Delaware</font></b></p></td> <td width=175 style="WIDTH:130.95pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>000-11254</font></b></p></td> <td width=170 style="WIDTH:127.45pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>11-2622630</font></b></p></td></tr> <tr> <td width=194 style="WIDTH:145.7pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(State or other jurisdiction<br>of incorporation)</font></p></td> <td width=175 style="WIDTH:130.95pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(Commission<br>File Number)</font></p></td> <td width=170 style="WIDTH:127.45pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(IRS Employer</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Identification No.)</font></p></td></tr></table></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <div style=page:WordSection1 align=center> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=349 style="WIDTH:261.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>3150 Almaden Expressway, Suite 250</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>San Jose, CA</font></b></p></td> <td width=337 style="WIDTH:252.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=FR>95118</font></b></p></td></tr> <tr> <td width=349 style="WIDTH:261.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(Address of principal executive offices)</font></p></td> <td width=337 style="WIDTH:252.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt"> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Registrant&#146;s telephone number, including area code:&nbsp;&nbsp;<b>(408) 708-9808</b></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>(Former name or former address, if changed since last report)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'><a name=up><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:</font></a><font style='FONT-SIZE:13.5pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'><br><br></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'><a name=Check1><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font></a><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</font><font style='FONT-SIZE:13.5pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'><br><br></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; TEXT-INDENT:0.5in; page:WordSection1'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Securities registered pursuant to Section 12(b) of the Act:&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <div style=page:WordSection1 align=center> <table width=85% bordercolor=transparent style="WIDTH:85%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=47% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Title of each class</font></b></p></td> <td width=1% style="WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center>&nbsp;</p></td> <td width=20% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:20%; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Trading Symbol(s)</font></b></p></td> <td width=1% style="WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center>&nbsp;</p></td> <td width=31% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:31%; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Name of each exchange on which registered</font></b></p></td></tr> <tr> <td style="PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Common Stock, par value $0.01 per share</font></p></td> <td style="PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td style="PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>ANIX</font></p></td> <td style="PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td style="PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>The NASDAQ Stock Market LLC</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center><font style=FONT-SIZE:10pt lang=EN-IN>1</font></p> <div style=page:WordSection1> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <div style=page:WordSection1><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div> <div style=page:WordSection1>&nbsp;</div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.5in; page:WordSection1'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Emerging growth company&nbsp;</font><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</font><font style="FONT-SIZE:10pt; FONT-FAMILY:Wingdings; COLOR:black">o</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; TEXT-INDENT:2.25pt; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center><font style=FONT-SIZE:10pt lang=EN-IN>2</font></p> <div style=page:WordSection1> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; TEXT-INDENT:2.25pt; page:WordSection1' align=center></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; TEXT-INDENT:2.25pt; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; MARGIN:0in 0in 0pt; page:WordSection1'><b><font style="FONT-SIZE:11pt; COLOR:#333333">Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Events.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><font style="FONT-SIZE:11pt; COLOR:#333333">On July 2, 2020, Anixa Biosciences, Inc. issued a press release announcing that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations, including continued development of its breast cancer vaccine, CAR-T therapy and Covid-19 discovery technologies and expanding its therapeutics portfolio.&nbsp; As part of this realignment, the company has suspended development of the Cchek&#153; liquid biopsy technology. &nbsp;A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><b><font style="FONT-SIZE:11pt; COLOR:#333333">Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><font style="FONT-SIZE:11pt; COLOR:#333333">(d) Exhibits</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><font style="FONT-SIZE:11pt; COLOR:#333333">The following exhibits are filed with this Current Report on Form 8-K:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><font style="FONT-SIZE:11pt; COLOR:#333333">Exhibit No.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Description</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in; page:WordSection1'><font style="FONT-SIZE:11pt; COLOR:#333333">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release dated July 2, 2020 </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center><font style=FONT-SIZE:10pt lang=EN-IN>3</font></p> <div style="VERTICAL-ALIGN:baseline; BACKGROUND:white; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1" align=center><font lang=EN-IN> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"'>SIGNATURE</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; TEXT-INDENT:0.5in; page:WordSection1'><font style='FONT-FAMILY:"Times New Roman","serif"'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%; page:WordSection1'>&nbsp;</p> <div style=page:WordSection1> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=51% nowrap style="HEIGHT:15pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"' lang=EN-IN>Dated: July 2, 2020</font></p></td> <td width=48% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:15pt> <td width=51% nowrap style="HEIGHT:15pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=48% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-IN>ANIXA BIOSCIENCES, INC.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=51% nowrap style="HEIGHT:15pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=48% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:48%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:20pt; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15.75pt> <td width=51% nowrap style="HEIGHT:15.75pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-IN>By:&nbsp;</font></p></td> <td width=44% nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:44%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-IN>/s/ Amit Kumar</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=51% nowrap style="HEIGHT:15.75pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=44% nowrap style="HEIGHT:15.75pt; WIDTH:44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-IN>Name: Dr. Amit Kumar</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=51% nowrap style="HEIGHT:15.75pt; WIDTH:51%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15.75pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=44% nowrap style="HEIGHT:15.75pt; WIDTH:44%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-IN>Title: President and Chief Executive Officer</font></p></td></tr></table></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%; page:WordSection1' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:107%'>4</font></p></body>
<!-- EDGAR Validation Code: 401DD15D -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head> <title>Exhibit 99.1</title></head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Exhibit 99.1</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><i><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'></font></u></i>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><i><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><i><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'></font></u></i>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>SAN JOSE, Calif., July 2, 2020 /PRNewswire/</font></b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>-- <u><font style=COLOR:blue>Anixa Biosciences, Inc.</font></u> (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations.&nbsp; As part of this realignment, the company has suspended development of the Cchek&#153; liquid biopsy technology.&nbsp; </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Going forward, Anixa&#146;s operations will center entirely on the development and expansion of its therapeutics and vaccine portfolio, which includes a cancer immunotherapy program being developed in partnership with the Moffitt Cancer Center, that uses chimeric endocrine receptor T-cell (CER-T) technology, a novel type of CAR-T.&nbsp; Anixa is also developing a cancer vaccine technology addressing breast cancer with a specific focus on triple negative breast cancer (TNBC), the most lethal form of the disease, in partnership with the Cleveland Clinic.&nbsp; Anixa will continue drug discovery and development of Covid-19 therapies, in partnership with OntoChem, GmbH.&nbsp; In addition, Anixa will continue to examine emerging therapeutic technologies for further development.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>"Due to the evolving dynamics of the diagnostics market during this pandemic and projected disruptions in this industry, we see greater opportunity to benefit patients and our shareholders as a therapeutics-directed company,&#148; said Amit Kumar, Ph.D., Chief Executive Officer of Anixa.&nbsp; "The pandemic and market forces have made it clear that we need to pivot.&nbsp; Our confidence in the Cchek&#153; technology remains undiminished, but we feel the prudent decision is to suspend work on diagnostics at this time.&#148;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Dr. Kumar continued, &#147;Anixa is a company built on the efficient use of capital.&nbsp; Capital allocation decisions are made based on the potential to provide the highest return to shareholders.&nbsp; We are all aware of the challenges to various industries caused by the coronavirus pandemic.&nbsp; The diagnostics industry is not immune, and considering this, as well as certain characteristics of our program, we have chosen this course of action.&nbsp; This decision will free up capital that we can devote to advance our existing therapeutic programs and to in-license and initiate innovative new assets that will help drive the greatest value for our shareholders.&#148;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-FAMILY:"Arial","sans-serif"' lang=EN-IN>1</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-IN> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>About Anixa Biosciences, Inc.</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.&nbsp; Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.&nbsp; The company&#146;s vaccine portfolio consists of a technology focused on the immunization against &alpha;-Lactalbumin to prevent triple negative breast cancer (TNBC).&nbsp; Anixa continually examines emerging technologies in complementary fields for further development and commercialization.&nbsp; Additional information is available at <u><font style=COLOR:blue>www.anixa.com</font></u>.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Forward-Looking Statements:&nbsp; Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp; Forward-looking statements are not statements of historical facts, but rather reflect Anixa&#146;s current expectations concerning future events and results.&nbsp; We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.&nbsp; Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.&nbsp; These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.&nbsp; We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.&nbsp; You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>###</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Anixa contact:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Mike Catelani</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:blue'>mcatelani@anixa.com</font></u></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>408-708-9808</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:blue'>Tiberend Strategic Advisors, Inc.</font></u></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Miriam Miller (Investors)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:blue'>mmiller@tiberend.com</font></u></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>212-375-2694</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>Johanna Bennett (Media)</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><u><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:blue'>jbennett@tiberend.com</font></u></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"'>212-375-2686</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%' align=center><font style='FONT-FAMILY:"Arial","sans-serif"'>2</font></p></div></body>
<!-- EDGAR Validation Code: 5B90E566 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
